Anti-aging biotech company NewLimit has raised USD 40 million in a Series A funding round led by Dimension, Founders Fund, and Kleiner Perkins. Investors such as Eric Schmidt, Elad Gil, Garry Tan, and Fred Ehrsam also participated. The latest funding adds to the initial USD 110 million from the founders.
The funds will be used to support its workforce.
NewLimit is a biotechnology company focused on treatments that target aging by identifying transcription factors that can epigenetically reprogram cells using machine learning. With a focus on T cells, they aim to rejuvenate the immune systems of older individuals and develop products that target aging and associated diseases, such as fibrosis, infectious disease, and neurodegenerative disease.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.